Analysis of commercial spectinomycin samples with ion-pairing reversed-phase LC coupled with electrospray ionization tandem MS (LC/ESI-MS/MS) indicates that eight additional compounds are present, including actinamine, (4R)-dihydrospectinomycin, (4S)-dihydrospectinomycin and dihydroxyspectinomycin, as well as four new impurities reported, to our knowledge, for the first time. The structures of these compounds were elucidated by comparing their fragmentation patterns with known structures, and NMR was employed to characterize and distinguish (4R)-dihydrospectinomycin and (4S)-dihydrospectinomycin. Identification of dihydrospectinomycin isomers is necessary because (4R)-dihydrospectinomycin is a minor active pharmaceutical ingredient of spectinomycin, whereas (4S)-dihydrospectinomycin is considered to be an impurity (impurity C) by the European Pharmacopoeia (Ph. Eur.).
INTRODUCTION
Spectinomycin is a broad-spectrum aminoglycoside antibiotic that has been widely used to treat human and animal infections. Spectinomycin was originally developed to treat Neisseria gonorrhoeae infections in patients allergic to penicillin, but it is presently used to treat various aerobic Gram-negative and Gram-positive organisms 1 and Mycoplasma sp. 2, 3 in various bacterial respiratory and enteric infections.
Spectinomycin is produced by Streptomyces spectabilis. Spectinomycin contains several biosynthetically related compounds including (4S)-dihydrospectinomycin, (4R)-dihydrospectinomycin and dihydroxyspectinomycin. 4, 5 Strong acidic hydrolysis can produce actinamine (impurity A), and in basic solutions, actinospectinoic acid (impurity B) is formed. 6 Other impurities have been described in the European Pharmacopoeia (Ph. Eur.) 7 (Figure 1 ).
Pharmaceutical safety is influenced by impurities present in manufactured products, [8] [9] [10] [11] and impurities may depend on the manufacturing process and compromise product quality. Thus, impurity characterization is necessary to ensure the safety of commercial spectinomycin.
Evaporative light scattering detection (ELSD) is a universal approach for analyzing many non-UV-absorbing analytes. 6, [12] [13] [14] [15] [16] [17] [18] [19] Frequently, the mobile phase from ELSD is transferred to MS detection because it contains volatile salts, unlike pulsed electrochemical detection that has no volatile mobile phase. 20, 21 Thus, MS can elucidate structural impurities in various aminoglycosides. [22] [23] [24] [25] [26] Specifically, spectinomycin analysis by LC/tandem MS (LC-MS n ) has been reported by Wang et al. 27 Impurities-C ((4S)-dihydrospectinomycin) and D (dihydroxyspectinomycin)-were identified in commercial spectinomycin. However, dihydrospectinomycin isomers ((4R)-or (4S)-dihydrospectinomycin) could not be distinguished by LC-MS n only and required further analysis including NMR. Meanwhile, several other impurities exceeding the International Conference on Harmonization (ICH) identification threshold 11 were also observed in commercial spectinomycin and required comprehensive characterization.
Here we report an improved volatile LC-ELSD method based on the current literature 27 that we then improved with MS. Impurities within seven commercial samples from five manufacturers were compared, and eight related substances were fully characterized by the LC system coupled with electrospray ionization MS (LC/ESI-MS/MS) in commercial spectinomycin samples including the minor active pharmaceutical ingredient (API) (4R)-dihydrospectinomycin. With NMR, we characterized the stereo-structure of dihydrospectinomycin ((4R)-or (4S)-dihydrospectinomycin) obtained by reduction of spectinomycin with sodium borohydride (NaBH 4 ) in methanol. Three known related substances (impurities A, C and D) and four new yet undescribed substances were also identified.
RESULTS AND DISCUSSION
Development and optimization of the LC-MS method First, 0.1 M trifluoroacetic acid (TFA) aqueous solution for isocratic elution was selected as a mobile phase because it offered good separation and a sharp peak with LC-ELSD. 27 Optimized LC-ELSD system specificity was confirmed by separation of sample 1 and the impurity mixture solution. This approach was validated with a pulsed electrochemical detection method described in the Ph. Eur. 7 The final LC-ELSD method is detailed in Methods/Experimental section.
Next, TSKgel C 18 , Venusil C 18 and Phenomenex C 18 columns were selected as recommended by the antibiotic-column selection database. 28 Considering the total analysis time and peak shape, the TSKgel ODS-100V column was most suitable for MS because of its small particle size and short column length. Data repeatability and robustness offered by the column were validated.
LC conditions were then optimized. Because of ion suppression produced by TFA, a lower concentration of TFA (0.04 M) and postcolumn addition of 70% methanol (0.5 ml min -1 ) were applied to enhance ionization to stabilize the spray and increase the signals. Concurrently, to increase the amount of impurities injected, ensure detection and minimize possible contamination caused by the principal peak, valve switching technology was employed to remove the concentrated main peak of spectinomycin (from 10.5 to 12 min) during characterization of related substances in commercial spectinomycin. A typical chromatogram of sample 1 obtained by LC/ESI-MS is shown in Figure 2 . Chemical structures of spectinomycin and its known impurities listed in the Ph. Eur. 7 indicate that fragile positions are ring C groups (that is, hydroxyls) and not ring A groups during fermentation. The abundance of the product ion at m/z 207 indicates that hydroxylation sites mostly likely occur in ring C, partly because of the strong steric effect from the two methylamino groups in ring A. The protonated molecules at m/z 333 and 335 all yield the characteristic product ions at m/z 207 (F1), 189 (F2) and 158 (F3) by the consecutive loss of ring C (À126u (spectinomycin)/ À128u ((4S)-dihydrospectinomycin)), water ( À18u) and a methylamino group ( À31u), respectively. This also indicates the presence of a nonmodified ring A that was confirmed by actinamine MS 2 spectra. The loss of water at the C-4 position ( À18u) was observed (product ion F4 at m/z 317) in the (4S)-dihydrospectinomycin MS 2 spectrum. A loss of spectinomycin was 28u. This is a product ion F4 at m/z 305, corresponding to a loss of carbon monoxide. The product ion F5 corresponding to the loss of the acetaldehyde group (CH 3 CHO, À44u) from ring C confirms the substituent group(s) at C-4 and C-3. For example, the product ions F5 of spectinomycin at m/z 289 and (4S)-dihydrospectinomycin at m/ z 291 verify that their C-4 substituents are carbonyl ( ¼ O) and hydroxyl (-OH), respectively. Characterization of the stereo-structure of dihydrospectinomycin obtained by reduction of spectinomycin with NaBH 4 in methanol by NMR Identification of dihydrospectinomycin isomers is critical: (4R)-dihydrospectinomycin is a minor API component of spectinomycin, whereas (4S)-dihydrospectinomycin is an impurity (impurity C, see Figure 1 ). 7 Dihydrospectinomycin is produced by reduction of spectinomycin with NaBH 4 in methanol (see Methods/Experimental section) and NMR spectroscopy confirmed its configuration, including the C-4 in ring C. The assignments of C and H atoms of dihydrospectinomycin were verified based on its 1 H-and 13 C-NMR data (see Table 1 ). Two-dimensional experiments such as heteronuclear single quantum coherence (HSQC) and heteronuclear multiple-bond correlation were employed to assign spectra, especially for two methylamino groups. More importantly, the absolute configuration of the stereocenter of C-4 was identified with 1 H-1 H rotatingframe Overhauser effect spectroscopy (ROESY) data ( Table 1) . The ROESY spectrum clearly shows a correlation between H-10a and H-2, both of which correlate to H-4. This suggests that the three protons are adjacent to each other and on the same side of ring C. Because the absolute configurations of C-10a and C-2 were known as 10aS and 2R, respectively, the absolute configuration of C-4 in the structure of dihydrospectinomycin was thus characterized as 4S.
Investigation of compounds present in commercial bulk samples of spectinomycin Seven commercial samples from different origins were screened for impurities using LC-ELSD and LC-MS (Table 2) . A double logarithmic curve obtained with reference solutions was used to quantify these impurities. Based on the fragmentation behavior of known components ( Figure 3a) and knowledge of known fragmentation mechanisms, 29 the impurities in different samples were investigated by LC-MS n .
Eight related substances were identified in the commercial samples including (4R)-dihydrospectinomycin (minor API), actinamine (impurity A), (4S)-dihydrospectinomycin (impurity C) and dihydroxyspectinomycin (impurity D). In addition, four new related substances were identified that, to the best of our knowledge, have not been reported. The proposed structures of these compounds are shown in Figure 1 . The loss of ring C ( À176u) with the cleavage at ring B observed in Figure 4a ) is 48u more than the corresponding loss ( À128u, that is, 335 À207 ¼ 128u) obtained with (4S)-dihydrospectinomycin. Its much shorter RT and abundant losses of water molecules ( À18u) in its [M þ H] þ CID spectrum revealed that the 48u difference may be because of the presence of three additional polar hydroxyl groups in ring C. No product ion corresponding to the loss of methanol ([M þ H-CH 3 OH] þ , m/z 351) was observed, indicating its C2-CH 3 was not replaced by -CH 2 OH. Thus, the possible positions of the additional hydroxyl groups were identified as C3, C2 and C-10a, respectively, in comparison with the structure of (4S)-dihydrospectinomycin.
The proposed structure of UNK1 (see Figure 1 ) can be further demonstrated by the following observations: (1) after consecutive losses of two water molecules, keto-enol tautomerism of the product Figure 3b . The subsequent neutral loss of 28u was because of the loss of carbon monoxide at C-4 in accordance with that of spectinomycin (F4). (2) Next, the subsequent loss of 44u was in accordance with that of spectinomycin or (4S)-dihydrospectinomycin (product ion: F5) as shown in Figure 3a , confirming its C2-CH 3 was normal. (3) The loss of 56u may be because of the combined loss of ethylene (CH 2 ¼ CH 2 , À28u) and carbon monoxide ( À28u). The plausible fragmentation pathway of UNK1 is shown in Figure 3b . Figure 4b . Similar to UNK1, its loss of ring C ( À160u) is 32u higher than that of (4S)-dihydrospectinomycin ( À128u). The shorter RT and abundant losses of water molecules in its [M þ H] þ CID spectrum indicate that two additional hydroxyl groups are located in ring C. The subsequent losses of 28u, 44u and 56u are similar to those of UNK1 (Figure 3b ). Based on these results, the proposed structure of UNK2 is shown in Figure 1 .
The RTs of UNK3 and UNK2 are close to each other, indicating similar polarities. The protonated molecule of compound UNK3 ([M þ H] þ m/z 369) in peak 4 and its loss of ring C ( À162u) (see Figure 4c ) are both 2u higher than those of UNK2. This suggests UNK3 may be the ring-opened derivative of UNK2. The abundant losses of water molecules (3 Â 18u) in its [M þ H] þ CID spectrum confirmed the presence of the additional hydroxyl groups in ring C. The loss of 28u (carbon monoxide) was because of keto-enol tautomerism after water molecule loss, similar to that of UNK1. The possible structure of UNK3 is shown in Figure 1 .
The compound in peak 5 ([M þ H] þ m/z 351) was identified as dihydroxyspectinomycin (impurity D). 7 As shown in Figure 4d , the characteristic ions at m/z 207 (F1), 189 (F2) and 158 (F3) revealed the presence of a normal ring A. The loss of ring C ( À144u) is 16u higher than the corresponding loss ( À128u) obtained with (4S)-dihydrospectinomycin and this indicates one additional hydroxyl group is located in ring C. Its shorter RT versus (4S)-dihydrospectinomycin confirmed that peak 5 has one additional hydroxyl group. Its fragmentation behavior after loss of one water ( À18u) is similar to that of (4S)-dihydrospectinomycin (that is, the subsequent loss of one water ( À18u) or acetaldehyde ( À44u)) that further confirmed the compound in peak 5 was dihydroxyspectinomycin. Its fragmentation pathway agreed with reports in the literature. 27 The ). This suggests its ring A was aberrant with 6-N-desmethyl or 8-N-desmethyl. Two hydroxyl groups adjacent to methylamino group at C8 could produce a stronger steric effect on the methylamino group at C8 than that at C6. Thus, the compound with 6-N-desmethyl is more likely to be present in the fermentation process of spectinomycin. An aberrant ring A was proposed based on the structure of Ndesmethyl-spectinomycin (impurity E, see Figure 1 ). The other fragmentation behaviors were similar to those of dihydroxyspectinomycin. Thus, peak 6 in UNK4 ([M þ H] þ m/z 337) was identified as N-desmethyldihydroxyspectinomycin (see Figure 1) .
The protonated molecules ([M þ H] þ m/z 335) and the [M þ H] þ CID spectra of the compounds in peaks 8 and 9 are the same as those of (4S)-dihydrospectinomycin and this indicates that they are isomers. The RT of the compound in peak 9 was the same as that of (4S)-dihydrospectinomycin prepared in this study. Thus, the compounds corresponding to peaks 8 and 9 were identified as (4R)-dihydrospectinomycin and (4S)-dihydrospectinomycin, respectively.
Comparison of different bulk samples. The impurity profiles of seven commercial samples from five different manufacturers were investigated by both LC-MS and LC-ELSD ( Impurities in commercial spectinomycin Y Wang et al unique impurities that are not uncommon because different strains can be used for the fermentation processes. The largest impurity was dihydroxyspectinomycin (impurity D). (4R)-dihydrospectinomycin (minor API) was present in almost all samples, whereas its stereo-isomer of (4S)-dihydrospectinomycin (impurity) was not. The newly identified impurities, such as UNKs 3 and 4, were also found in all samples. In contrast, impurities E, F and G were not detected in all samples. There is a significant difference between the impurity profiles of samples 1 and 2, although both were from company A, suggesting that production or the fermentation process might be inconsistent.
METHODS/EXPERIMENTAL SECTION Reagents and samples
HPLC-grade methanol was obtained from Fisher Scientific (Fairlawn, NJ, USA). HPLC-grade TFA was supplied by Merk-Schuchardt (Hohenbrunn, Germany). A Milli-Q water purification system (Millipore, Billerica, MA, USA) was used to further purify glass-distilled water. Reference samples of spectinomycin and impurities A (actinamine) and B (actinospectinoic acid) were provided by National Institutes for Food and Drug Control, Beijing, People's Republic of China. The descriptors of impurities A-G are consistent with those presented in Ph. Eur. 7.0. 7 Seven batches of samples 1-7 of spectinomycin were obtained from five different manufacturers (companies A-E). Dihydrospectinomycin (sodium salt) was prepared as follows: 18.9 g of spectinomycin hydrochloride was added to 625 ml of methanol, and the solution was stirred for 30 min until opacification. Gaseous ammonia was then introduced into the solution to adjust the pH to 10.5. Then, 6.4 g of NaBH 4 was added gradually while cooling on an ice bath. After standing for B2.5 h at ambient temperature, the solution was filtered and adjusted to pH 3.0 with 6 M hydrochloric acid. The residue obtained by vacuum evaporation at room temperature was then added to 188 ml of methanol and evaporated again. The operation was repeated in another 63 ml of methanol and filtered. To this second solution, 250 ml of ether was added and the precipitate was removed by filtration/evaporation at room temperature (purity by ELSD X95%).
Solution preparation
A mixture of actinamine, actinospectinoic acid, spectinomycin and dihydrospectinomycin in distilled water was prepared at 0.1 mg ml -1 each as the impurity mixture solution. Sample solutions in distilled water were prepared at 6 mg ml -1 . Reference solutions were 0.03, 0.12 and 0.3 mg ml -1 (corresponding to 0.5-5.0% of the sample concentration). Sample solutions were prepared immediately before use to avoid anomer formation. Dihydrospectinomycin was freshly prepared in deuterated DMSO at B20 mg ml -1 for the NMR experiment.
Instrumentation
The LC-ELSD was performed on a Shimadzu LC-20A HPLC (Kyoto, Japan) system equipped with LC-20AT binary pumps, a DGU-20A 3 vacuum degasser, a SIL-20AC autosampler, a CTO-10AS VP column oven, an Alltech 2000ES ELSD (Deerfield, IL, USA), an automatic air source generator (Type GCK3308, BCHP, Beijing, China) and Shimadzu LC-solution software was used for data processing.
LC/ESI-MS/MS consisted of a 3201 S1-2 binary pump, a 3202 S1-2 vacuum degasser, a 3014 S1-2 column heater, a 3012 S1-2 column switch system, a 3133 
Chromatographic conditions
The mobile phase for LC-ELSD contained 0.1M of TFA in water for isocratic elution without organic solvent (0.5 ml min -1 
MS
Optimization and MS/MS analysis of spectinomycin samples were carried out according to the instrument manufacturer's instructions. ESI was operated in positive ion mode with an enhanced MS scanning mode for MS1 and enhanced product ion scanning mode for MS2. The optimized MS conditions were ESI-positive ionization mode, declustering potential of 60 V, entrance potential of 10 V, collision energy of 30 V, curtain gas: 20.0 l min -1 , ion source gas 1: 65.0 l min -1 , ion source gas 2: 60.0 l min -1 , ion spray: 5500.0 V, temperature: 500.0 1C and interface heater: on. The acquisition of the firstorder mass spectra (Q1 scan) was from 100 to 500u. The ions of interest were isolated in the ion trap and activated at collision energy of 30 V to get enhanced product ion spectra in the range of 50-400u. The 'Precursor Ion (Prec)' and 'Neutral Loss (NL)' methods of Analyst software were also used to confirm the individual protonated molecules and proposed fragmentation pathways. Valve switching cut off the major spectinomycin peak during impurity characterization.
NMR spectroscopy
The 1 H, 13 C and 1 H-1 H ROESY as well as heteronuclear multiple-bond correlation and heteronuclear single quantum coherence NMR experiments were employed to elucidate the stereo-structure of dihydrospectinomycin. The two possible structures-(4R)-or (4S)-dihydrospectinomycin-were obtained by reduction of spectinomycin with NaBH 4 in methanol. NMR experiments were performed in DMSO at 251C. The 1 H, 13 C and 1 H-1 H ROESY chemical shifts were reported on the d scale in p.p.m. relative DMSO-d6, respectively. A relaxation delay of 1 s and a mixing time of 300 ms were used in the ROESY experiment.
Experimental details on NMR data are available as Supplementary Information.
CONCLUSION
Using the LC-MS n capability of the 3200Q TRAP mass spectrometer, several impurities in commercial spectinomycin samples were characterized: four known compounds and four new substances. The stereo-structure of dihydrospectinomycin obtained by reduction of spectinomycin with NaBH 4 in methanol was identified as (4S)-dihydrospectinomycin according to 1 H-1 H ROESY NMR. Spectinomycin sample impurities from the five manufacturers were different with respect to type and amount according to LC-MS n and LC-ELSD. The major impurities observed were dihydroxyspectinomycin (impurity D) and the minor API (4R)-dihydrospectinomycin, both of which arise from fermentation.
Meanwhile, because isomers could not be distinguished by only LC-MS, the spatial configuration of the chiral carbons in ring C of the four new related substances require confirmation by other techniques, such as NMR. However, because of their low abundance and the difficulty in purification of each, these experiments may be challenging.
